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The objective of this study was to prepare azithromycin (AZI) sustained-release products in
order to allow for a high dose to be administered, reduce gastrointestinal side-effects and in-
crease the compliance of patients. AZI sustained-release tablets with different release per-
formance (F-I: T100% ¼ 3 h and F-II: T100% ¼ 8 h in pH 6.0 phosphate buffer) were successfully
prepared by wet granulation. The in vitro release rate and drug release mechanism were
studied. The release rate of F-I was affected by dissolutionmediawith different pH, but not for
F-II. HixsoneCrowell model was the best regression fittingmodel for F-I and F-II. Additionally,
F-I and F-II both belonged to non-Fick diffusion. Oral pharmacokinetics of the two tablets and
one AZI dispersible tablet as reference were studied in six healthy beagle dogs after oral
administration. Comparedwith the reference, the Cmax of F-I and F-II were decreased, and the
Tmax were prolonged, in that case which meet the requirement of sustained-release tablets.
The relative bioavailability of F-I and F-IIwere 79.12% and 64.09%. T-test of AUC0e144, andAUC0
eN for F-I and F-II indicated there was no significant difference between F-I and F-II. These
mean that the extended release rate did not induce different pharmacokinetics in vivo.
ª 2014 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction
Azithromycin (AZI) expands spectrum of antibiotic activity
and improves tissue pharmacokinetic characteristics relative321.
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University. Production anto erythromycin [1]. It is absorbed rapidly and has a two-
compartment model with peroral administration, while its
treatment often has adverse effect on the gastrointestinal
tract [2]. Therefore, new drug delivery technology should be).
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for a high dose to be administered and a full course of anti-
biotics to be given in a single dose. Azithromycin has an
extremely long half-life [3]. This makes it well suited to a
single-dose administration. FDA had approved one AZI
extended release (Zmax, Pfizer Inc), that was a novel sing-
dose administration formulation. It is currently approved for
the treatment of community acquired pneumonia and acute
bacterial sinusitis. Recent studies have shown that sustained-
release AZI tablets achieve high drug exposure on the first day
of therapy at infection sites compared with AZI immediate-
release tablets [4,5].
The formulations of sustained-release drug delivery sys-
tems wish to achieve desired release rates, decrease the
number of daily administrations, improve compliance and
minimize side-effects. A hydrophilic matrix is one of sus-
tained-release formulations. It is a homogeneous dispersion
of drugmolecules within a skeleton in which one or several of
the excipients, such as xanthan gum, cellulose derivatives,
alginate sodium or carbopol [6].
HPMC is the most widely used as a drug release retardant
excipient in hydrophilic matrices. It is soluble in water, non-
ionic, stable at a pH between 3.0 and 11.0 and resists
enzyme attack [7]. Xanthan gum is a high molecular weight
extracellular heteropolysaccharide, produced by fermenta-
tion with the gram-negative bacterium Xanthamonas can-
pestris. It is widely used in the food industry and in pharmacy
practice [8]. Some authors have reported that xanthan gum
affords zero-order or at least time-independent release ki-
netics [9,10]. In this study, HPMC and xanthan gumwere used
as hydrophilic matrix to prepare sustained-release
formulations.
In this study, AZI sustained-release tablets with different
release rates (T100% ¼ 3 h and T100% ¼ 8 h in pH 6.0 phosphate
buffer) were prepared. The release performances of them
were studied in dissolution media with different pH values.
Drug release mechanism and the pharmacokinetics of them
were studied in detail. Beside, a fast, selective and highly
sensitive UPLC-MS-MS for determination of AZI plasma con-
centration of beagle dogs was developed.Table 1 e Compositions of 500 mg AZI sustained-release
tablets.
Ingredients (per tablet) F-I F-II
AZI (mg) 500 500
HPMC K100LV (mg) 80 90
Xanthan gum (mg) e 20
Lactin (200 screen) (mg) 260 220
MCC (mg) 150 160
Magnesium stearate (mg) 10 10
Ethanol (80%) qs e
Ethanol (90%) e qs
*qs indicates quantity sufficient.2. Materials and methods
2.1. Materials
AZI was purchased from Shandong Zhongya Pharmaceutical
Co., Ltd. (Shandong, China). Hydroxypropyl methyl cellulose
(HPMC K100LV) was purchased from Colocrcon Co., Ltd.
(Shanghai, China). Lactin (Granulac-200, batch no. 0321) was
purchased from Meggle Co., Ltd. (Germany). Microcrystalline
cellulose (MCC, batch no. 20071102) was purchased from
Yingkou Aoda Pharmaceutical Co., Ltd. (Yingkou, China).
Magnesium stearate was purchased from Tianjing Bodi
Chemical Factory Co., Ltd. (Tianjing, China). AZI and roxi-
thromycin (ROX) standards were purchased from the National
for Control of Pharmaceutical and Biological Products (China).
AZI dispersible tablet (250 mg, batch no. 091019) was pur-
chased from Jiangsu Huanghe Pharmaceutical Co. Ltd.
(Jiangsu, China). All other reagents were either of analytical orchromatographic grade. Double distilled water was used
throughout the study.2.2. Preparation of sustained-release tablets
Formulations I and II were prepared by wet granulation
technique (Table 1). All the powders were passed through 100
mesh. Required quantities of drug and excipients were mixed
thoroughly, and a sufficient volume of wetting agent (80% or
90% Ethanol) was added slowly. After enough cohesiveness
was obtained, the mass was sieved through 20 mesh. The
granules were dried at 60 C for 2 h. Then, the granules were
retained on 20mesh.Magnesium stearatewas finally added as
glidant and lubricant. Finally, the tablets were compressed.
Tablet hardness was controlled between 8.0 and 10.0 N, and
the tablet weight was 1.0 g. Each tablet contained 500 mg of
AZI and other pharmaceutical ingredients as listed in Table 1.2.3. In vitro release tests
The in vitro release studies were carried out using RCZ-6B
dissolution apparatus (paddle method). The 900 mL dissolu-
tion medium was kept at 37 C and the rotating speed was
100 rpm. The dissolution media used were 0.1 mM HCL, ace-
tate buffer with pH 4.5, and phosphate buffers with pH 6.0, 6.8
and 7.0. F-I and F-II were used in all dissolution studies.
Samples were withdrawn from the dissolutionmedia at 0.5, 1,
1.5, 2 and 3 h for F-I, and at 1, 2, 4, 6 and 8 h for F-II. Samples
were passed through a 0.45 mm millipore filter and added
sulfuric acid solution, then assayed AZI by the UV method.2.4. Drug release mechanism
Drug release data were analyzed by various mathematical
models. Six kinetic models including zero order, first order
[11], Higuchi [12], RitgerePeppas [13], HixsoneCrowell [14] and
BakereLonsdale release equations were applied to process the
in vitro release data. The equations are showed in Table 2.
where Qt is the drug released fraction at time t, k0 is the
zero order release rate constant, k1 is the first order release
rate constant and kH is the Higuchi’s release rate constant, t is
the release time, n is the parameter that depends on the
release mechanism and the shape of the matrix tested. The
optimum values for the parameters present in each equation
were determined by linear or non-linear least-squares fitting
Table 2 e Models simulated for the release profiles of AZI sustained-release tablets.
Batch No. Model Equation r
F-I Zero-order model Qt ¼ 31.81t þ 9.887 0.9762
First-order model ln(96.43  Qt) ¼ 0.942t þ 4.57 0.9706
Higuchi diffusion model Qt ¼ 57.36t1/2  5.801 0.9889
Riteger-peppas model lnQt ¼ 0.7301lnt þ 3.829 0.9940
HixsoneCrowell model (1  Qt)1/3 ¼ 1  0.220t 0.9960
BakereLonsdale model 3/2[1  (1  Qt)2/3]  Qt ¼ 0.124t  0.047 0.9623
F-II Zero-order model Qt ¼ 11.71t þ 13.7 0.9649
First-order model ln(97.64  Qt) ¼ 0.631t þ 4.58 0.6140
Higuchi diffusion model Qt ¼ 36.02t1/2  3.497 0.9955
Riteger-peppas model lnQt ¼ 0.6201lnt þ 3.346 0.9955
HixsoneCrowell model (1  Qt)1/3 ¼ 1  0.085t 0.9975
BakereLonsdale model 3/2[1  (1  Qt)2/3]  Qt ¼ 0.05t  0.035 0.9823
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were calculated on the basis of correlation factors as r.2.5. In vivo pharmacokinetic study
The pharmacokinetics was studied in accordance with the
Guide for the Care and Use of Laboratory Animals. Six male
beagle dogs weighing 10e14 kg were used and divided into 3
groups randomly, and the studywas carried out in a crossover
experimental design with a washout period of one week. The
dogswere fasted for about 12 h prior to experiments, andwere
given water freely. The preparations (F-I, F-II and AZI
dispersible tablet) were administered orally at a single dose
of 500 mg. Five milliliter of blood samples were taken into a
heparinized blood collection tube via a detaining needle at
pre-dose, 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 7.0, 8.0, 12.0, 24.0, 48.0, 72.0,
96.0, 120.0 and 144.0 h post-dose. Four hours after dosing, dogs
were provided with a standard lunch. The plasma fraction
was obtained by centrifuging the samples at 3500 rpm for
10 min, and was stored at 20 C until analysis.
After precipitation protein by acetonitrile, the AZI con-
centrations in plasma were determined by liquid
chromatography-dual mass spectrometry (LC-MS/MS)
method. Roxithromycin (ROX) was used as internal standard.
The chromatographic separations were acquired on the
ACQUITY UPLC system (Waters Corp, Milford, Massachu-
setts) and BEH C18 column (50 mm  2.1 mm, 1.7 mm; Waters
Corp.) with a mobile phase composed of acetonitrile and
ammonia acetate (0e1 min: 50%e90% acetonitrile, 90% ace-
tonirile sustained 0.5min, 1.5e2.0min: 90%e50% acetonitrile).
The compounds were analyzed by multiple reaction moni-
toring (MRM) of the transitions of m/z 749/ 591 for AZI, and
m/z 838/ 158 for ROX.
The maximum plasma concentration of AZI (Cmax) and the
time to reach Cmax (Tmax) were read directly from the plasma
concentration versus time data. The area under curve (AUC)
was calculated using the linear trapezoidal rule up to the last
data points in plasma concentration-time curve. The elimi-
nation rate constant (k) was the slope of the terminal four
points in plasma concentration-time curve, and the half-life
of the preparation (t1/2) was calculated by 0.693/k. All values
were expressed as their mean  SD. (standard deviation). The
relative bioavailability values (F) were calculated using
following formula with AZI dispersible tablet as a reference:F ¼ AUCtest
AUCreference
 100% (1)
2.6. In vivo analysis method validation
2.6.1. Selectivity
Selectivitywas studied by comparing chromatograms of blank
plasma obtained from subjects with those of corresponding
standard plasma samples spiked with AZI, I.S., and plasma
sample after oral doses of AZI tablets.
2.6.2. Linearity and lower limit of quantification (LLOQ)
Calibration curves were prepared by making serial dilution of
the working stock and assaying standard plasma samples at
six concentrations of AZI ranging 25e5000 ng/ml. The cali-
bration curveswere constructed byweighted (1/x) least square
linear regression. The validation of LLOQ was conducted in at
least six different batches of blank plasma. It was validated
using an LLOQ sample for which an acceptable accuracy (RE)
within20% and a precision (R.S.D.) below 20%were obtained.
2.6.3. Precision and accuracy
For determining the intra-day accuracy and precision, a
replicate analysis of QC plasma samples of AZI was performed
on the same day, the run consisted of a calibration curve and
six replicates of each low,mid, and high concentration quality
control samples. The inter-day accuracy and precision were
assessed by analysis of three batches on different days. The
precision was expressed as the relative standard deviation
(R.S.D.) and the accuracy as the relative deviation (RD).
2.6.4. Extraction recovery and matrix effect
The extraction recovery of AZI was calculated by comparing
the peak areas of blank plasma sampleswhich adding AZI and
ROX before extraction to adding AZI and ROX after extraction.
This procedure was repeated for six replicates at three con-
centrations of 50, 1000, 4000 ng/ml. In order to evaluate the
matrix effect on the ionization of analyte, AZI at three con-
centration levels were added to the extract of 50 mL of blank
plasma, the corresponding peak areas (A) were comparedwith
those of the AZI standard solutions evaporated directly and
make the water instead plasma. The ration (A/B  100) % was
used to evaluate the matrix effect. The matrix effect of inter-
nal standard was also evaluated using the same method.
Fig. 1 e Dissolution of AZI sustained-release tablet F-I in
0.1 mM HCL, acetate buffer with pH 4.5, and phosphate
buffers with pH 6.0, 6.8 and 7.2. (Data are mean ± SD.,
n [ 6).
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The effect of freeze and thaw cycles on the AZI stability in
plasma was determined by analyzing AZI concentration (low,
mid and high concentration) in plasma samplewhichmeeting
four freeze-thaw cycles. After completion of every cycle, the
samples were analyzed and the experimental concentrations
were compared with the nominal values. The accuracy values
of three concentrations in four freeze-thaw cycles were
calculated.
In order to estimate the stability of AZI in the prepared
sample, three QC samples at low, mid and high concentration
were kept in sample room about 6 h. Then, the samples were
analyzed and the concentrations obtained were compared
with the nominal values.Fig. 2 e Dissolution of AZI sustained-release tablet F-II in
0.1 mM HCL, acetate buffer with pH 4.5, and phosphate
buffers with pH 6.0 and 7.2. (Data are mean ± SD., n [ 6).
Fig. 3 e Representative MRM chromatograms for
roxithromycin and azithromycin from (A) blank plasma
sample; (B) blank plasma with internal standard of
roxithromycin and azithromycin; (C) plasma sample with
internal standard Roxithromycin and Azithromycin.
Table 3 e The absolute recovery of AZI in dog plasma.
Azithromycin Roximythromycin
50 (ng/ml) 1000 (ng/ml) 4000 (ng/ml) 200 (ng/ml)
Recovery/% 85.15 84.91 95.40 88.65
76.68 86.93 95.23 92.40
81.78 74.56 99.42 98.64
81.13 78.77 75.76 86.49
90.61 78.05 79.32 103.16
95.22 81.97 87.50 91.58
Mean  SD/% 85.10  6.79 80.86  4.61 88.77  9.59 93.49  6.28
RSD/% 7.98 5.70 10.80 6.72
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3.1. Dissolution test
The in vitro dissolution profiles of F-I and F-II were shown in
Figs. 1 and 2. F-I released 100%within 3h, and F-II released100%
within 8 h. The release behavior of F-I was affected by pH of
dissolution medium. However, the release behavior of F-II was
not. The skeleton material of F-I is HPMC, which is a non-ionic
polymer. The property of HPMC is not dependent on the pH of
dissolution media. The solubility of AZI decreased with
increasing pH of media, inducing the release rate of F-I became
slowwith increasing pHofmedia. For F-II, the skeletonmaterial
is Xanthan gum, which is an anion polymer. The property of
Xanthan gum is dependent on the pH of dissolution media. In
acidic dissolution medium, the ions make the glass transition
temperature of Xanthan gum become higher [15,16], hydrating
rate becomes slowly. Then, in the early stages of release (about
0e3 h), it is difficult to form gel layer, resulting in the quick
release of drug. In the middle period, the ions decreases the
degreeofswelling, increases thestrengthofgel layer.Asaresult,
in the final stage of release, the drug release slowly.3.2. Drug release mechanism studies
In order to explore the mechanism of drug release, drug
release data were analyzed by six mathematical models. As
shown in Table 2, through various types of regression model
parameters and comparing, HixsoneCrowell model was the
best regression fitting degree for F-I and F-II. Additionally, the
data of F-I and F-II showed values of “n” in Riteger-peppas
model between 0.45 and 0.89, which could be attributed to
non-Fick Diffusion (Table 2).Table 4 e Stability of AZI in dog plasma under indicated
conditions (mean ± SD, n[ 3).
Added
(ng/ml)
Found
(ng/ml)
Accuracy/% RSD/%
50 51.2  1.67 102.4 3.26
Pretreatment
for 6 h
1000 937.3  42.52 93.73 4.53
4000 3806.1  59.35 95.15 1.55
50 52.03  5.40 104.06 10.38
Freeze-thaw
stability
1000 931.3  18.02 93.13 1.93
(36 h, n ¼ 3) 4000 3632.2  118.1 90.81 3.253.3. HPLC method validation for determination plasma
samples
3.3.1. Selectivity
No interference from endogenous substance was observed at
the retention time of AZI and ROX (Fig. 3).
3.3.2. Linearity and LLOQ
The standard calibration curves for AZI were linear over the
concentration range of 25.0e5000.0 ng/ml (r2 > 0.99). The
lower limit of quantification for AZI was 25.0 ng/ml with RE
within 20% and R.S.D. lower than 20%.
3.3.3. Precision and accuracy
The intra-day precision for low, middle and high QC levels of
AZI were 5.68%, 5.53% and 2.04%, and that of inter-day anal-
ysis were 5.39%, 7.49% and 10.05%. The accuracy of low,
middle and high QC levels of AZI were 99.48%, 103.10% and
97.59%.
3.3.4. Extraction recovery and matrix effect
The extraction recoveries of AZI from dog plasma were
85.10  6.79%, 80.86  4.61% and 88.77  9.59% at con-
centration levels of 50, 1000 and 4000 ng/ml (Table 3).Fig. 4 e Average azithromycin plasma concentration-time
curves following oral administration of the three
formulations in beagle dogs (Mean ± SD).
Table 5 e Pharmacokinetic parameters of reference, F-I and F-IIAZI tablets (mean ± SD, n[ 6).
ke (h
1) t1/2 (h) Cmax (ng/ml) Tmax (ng/ml) AUC0e144 (ng h/ml) AUC0eN (ng h/ml)
reference 0.01  0.00 73.71  46.60 5558.55  612.14 0.58  0.20 1,84,797.81  32,551.65 2,52,633.25  88,903.26
F-I 0.02  0.01 58.78  22.79 4115.13  1654.54 3.17  3.37 1,44,692.82  48,231.96 1,74,459.75  44,979.14
F-II 0.02  0.01 40.36  14.17 3429.68  166.01 4.83  3.60 1,14,174.34  41,553.65 1,24,340.64  46,512.13
Table 6 e One-side F-test and T-test results of main
parameters between F-I and F-II.
AUC0e144
(ng h/ml)
AUC0eN
(ng h/ml)
Cmax
(ng/ml)
F-test P > 0.05 P > 0.05 P < 0.05
T-test P > 0.05 P > 0.05 P > 0.05
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 9 ( 2 0 1 4 ) 1 5 5e1 6 1160As for matrix effect, all the ratios were between 85% and
115%, which means no matrix effect for AZI and ROX in this
method.
3.3.5. Stability
The stock solution of AZI in plasma was found to be stable at
sample room 7 C for 6 h, at freeze and thaw stability (Table 4).
The results from all stability tests presented demonstrated a
good stability of AZI over all steps of the determination.
The validation above all met the demands of accurate
quantification.
3.4. Pharmacokinetic study
Pharmacokinetic study of the two sustained-release tablets of
AZI compared with commercial available dispersible tablet
were investigated following oral administration of 500 mg in
dogs. The mean concentration-time profiles for the three AZI
tablets are shown in Fig. 4. The pharmacokinetic parameters
for the three formulations are shown in Table 5. The mean
peak plasma concentrations for F-I, F-II and AZI dispersible
tabletwere 4115.13, 3429.68 and 5558.55 ng/ml, and thesewere
achieved at 3.17, 4.83 and 0.58 h, respectively. Compared with
the reference, the Cmax of F-I and F-II were decreased, and the
Tmax were prolonged, in that case which meet the re-
quirements of sustained-release tablets. The relative
bioavailability of F-I and F-II were 79.12% and 64.09%.
Compared with the reference, the AUC0e144 of F-I and F-II
decreased significantly.
T-test of AUC0e144, AUC0eN and Cmax for F-I and F-II were
carried out (Table 6). We found there was no significant dif-
ference between F-I and F-II for AUC0e144, and AUC0eN, sug-
gesting that the different release rate did not induce different
pharmacokinetic in vivo. F-II which releases the drug slowly,
allowed for a high dose to be administered, reduced gastro-
intestinal side-effects, increased the compliance of patients.4. Conclusion
Two sustained-release AZI tablets (F-I and F-II) were prepared.
The release rate of F-I and F-II were T100% ¼ 3 h and T100% ¼ 8 h
in pH 6.0 phosphate buffer, respectively. However, the
AUC0e144 and AUC0eN of F-I and F-II were no significantlydifferent. F-II which releases the drug slowly, allowed for a
high dose to be administered, reduced gastrointestinal side-
effects, increased the compliance of patients, but did not
change the pharmacokinetic behavior. Xanthan gum was a
good skeleton material that made the release of AZI not
affect by pH of dissolution medium. The relative bioavail-
ability of F-I and F-II were 79.12% and 64.09% compared with
the reference.r e f e r e n c e s
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